417 related articles for article (PubMed ID: 28544128)
21. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands.
Veldhuijzen van Zanten SE; Jansen MH; Sanchez Aliaga E; van Vuurden DG; Vandertop WP; Kaspers GJ
Expert Rev Anticancer Ther; 2015 Feb; 15(2):157-64. PubMed ID: 25435089
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
[TBL] [Abstract][Full Text] [Related]
25. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
Kilburn LB; Kocak M; Schaedeli Stark F; Meneses-Lorente G; Brownstein C; Hussain S; Chintagumpala M; Thompson PA; Gururangan S; Banerjee A; Paulino AC; Kun L; Boyett JM; Blaney SM
Neuro Oncol; 2013 Jun; 15(6):759-66. PubMed ID: 23592571
[TBL] [Abstract][Full Text] [Related]
27. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
28. Pediatric glial tumors.
Cohen KJ; Broniscer A; Glod J
Curr Treat Options Oncol; 2001 Dec; 2(6):529-36. PubMed ID: 12057098
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
MacDonald TJ; Arenson EB; Ater J; Sposto R; Bevan HE; Bruner J; Deutsch M; Kurczynski E; Luerssen T; McGuire-Cullen P; O'Brien R; Shah N; Steinbok P; Strain J; Thomson J; Holmes E; Vezina G; Yates A; Phillips P; Packer R
Cancer; 2005 Dec; 104(12):2862-71. PubMed ID: 16315242
[TBL] [Abstract][Full Text] [Related]
30. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
[TBL] [Abstract][Full Text] [Related]
31. Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Aguilera DG; Mazewski C; Hayes L; Jordan C; Esiashivilli N; Janns A; Macdonald TJ
J Pediatr Hematol Oncol; 2013 Jan; 35(1):e42-6. PubMed ID: 23249962
[TBL] [Abstract][Full Text] [Related]
32. Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study.
van der Louw EJTM; Reddingius RE; Olieman JF; Neuteboom RF; Catsman-Berrevoets CE
Pediatr Blood Cancer; 2019 Mar; 66(3):e27561. PubMed ID: 30484948
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Baxter PA; Su JM; Onar-Thomas A; Billups CA; Li XN; Poussaint TY; Smith ER; Thompson P; Adesina A; Ansell P; Giranda V; Paulino A; Kilburn L; Quaddoumi I; Broniscer A; Blaney SM; Dunkel IJ; Fouladi M
Neuro Oncol; 2020 Jun; 22(6):875-885. PubMed ID: 32009149
[TBL] [Abstract][Full Text] [Related]
34. Pediatric diffuse intrinsic pontine glioma patients from a single center.
Kebudi R; Cakir FB; Agaoglu FY; Gorgun O; Ayan I; Darendeliler E
Childs Nerv Syst; 2013 Apr; 29(4):583-8. PubMed ID: 23224361
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Chassot A; Canale S; Varlet P; Puget S; Roujeau T; Negretti L; Dhermain F; Rialland X; Raquin MA; Grill J; Dufour C
J Neurooncol; 2012 Jan; 106(2):399-407. PubMed ID: 21858607
[TBL] [Abstract][Full Text] [Related]
36. Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.
Kaye EC; Baker JN; Broniscer A
CNS Oncol; 2014 Nov; 3(6):421-31. PubMed ID: 25438813
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
40. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma.
Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM
J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
